Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress

2023-10-24

基因疗法

WALTHAM, Mass., Oct. 24, 2023 /PRNewswire/ -- Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that the company will present preclinical data on its novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS) in a poster session at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, being held October 24-27, 2023, in Brussels, Belgium.

The poster presentation details are listed below and the full program can be found on the ESGCT website at www.esgctcongress.com.

Title: Engineered AAV capsids with significantly improved muscle and CNS tropism plus reduced liver and DRG expression compared to AAV9

Abstract Number: P084

Date: October 25, 2023, 6:15-7:30 PM CEST and October 26, 2023, 7:30-8:30 PM CEST

Presenter: John Reece-Hoyes, Ph.D., Senior Director, Head of Vector Biology, Affinia

About Affinia Therapeutics

Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' proprietary Affinia Rationally designed Therapeutics (ART) platform consists of three pillars intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. For more information, visit https://www.affiniatx.com.

SOURCE Affinia Therapeutics

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构